

Figure 1. Skin biopsy specimens, infiltrating cells, and overall survival. Immunohistochemical analysis of representative skin biopsy specimen (A), the cell count distribution of CD8⁺, CD163⁺, and CD1a⁺ cells (B), and the impact of MM on OS (C-D). (A) Tissue sections of skin biopsy were stained with hematoxylin and eosin (ai,bi,ci), or antibodies to CD8⁺ (aii, bii, cii), or CD163⁺ (aiii, biii, ciii) as detailed in "Methods." Shown are representative specimens of an MT/FM patient (ai-iii), a MT/MM patient (bi-iii), and an FT/MM patient (ci-iii). Original magnifications ×200. (B) Distribution of infiltrating cell counts (Bi, CD8⁺; Bii, CD163; and Biii, CD1a). (C) OS according to CD163⁺ cell counts (≤ 200 [FM] vs > 200 [MM]) in all patients. OS of patients with MM was significantly lower than that of those with FM (FM: 66.2% ± 10.6% at 1 year and 58.3% ± 11.4% at 3 years; MM: 37.8% ± 21.0% at 1 year and 37.8% ± 21.0% at 3 years, respectively; *P* = .005). (D) OS according to CD163⁺ cell counts (≤ 200 vs > 200) in 46 patients undergoing steroid treatments. OS of patients with MM was significantly lower than that of those with FM (FM: 57.7% ± 17.1% at 1 year and 50.7% ± 17.4% at 3 years; MM: 18.2% ± 22.7% at 1 year and 18.2% ± 22.7% at 3 years, respectively; *P* = .002).

the fact that skin biopsies can be performed safely without any critical complications, our results support the importance of conducting skin biopsies of posttransplantation skin lesions. In cases where macrophage-dominant infiltration is observed in a skin biopsy specimen,

macrophage-targeted therapies¹⁸⁻²³ could provide a clue to refractory GVHD.

In conclusion, macrophage infiltration of skin lesions after allo-SCT was shown to be a significant predictive factor for

Table 3. Analyses of risk factors for OS in all 104 patients

Parameter	Univariate		Multivariate	
	Hazard ratio (95% CI)	P	Hazard ratio (95% CI)	P
Older than 50 y	2.27 (1.23-4.20)	.009	—	—
High disease risk	1.87 (1.03-3.40)	.04	1.92 (1.06-3.50)	.03
Graft PB (vs BM)	2.04 (0.91-4.61)	.08	—	—
Unrelated donor	0.71 (0.40-1.29)	.26	—	—
HLA mismatch	1.13 (0.61-2.10)	.70	—	—
Conventional regimens	0.74 (0.39-1.39)	.35	—	—
Skin stage 3 or 4 at biopsy	1.11 (0.57-2.15)	.76	—	—
MT (> 100 CD8 ⁺ cells)	1.10 (0.59-2.08)	.76	—	—
MM (> 200 CD163 ⁺ cells)	2.38 (1.27-4.49)	.006	2.45 (1.30-4.61)	.006

— indicates not applicable.

refractory GVHD, as well as being a negative prognostic factor for OS. Our results indicate the importance of skin biopsies after allo-SCT and suggest the possibility of developing infiltrating cell-based strategies.

Acknowledgments

This study was supported in part by the Japan Leukemia Research Fund (S.N.) and in part by a Ministry of Health, Labor and Welfare of Japan Grant-in-Aid (K.M.).

References

- Gordon S. The role of the macrophage in immune regulation. *Res Immunol*. 1998;149(7):685-688.
- Stoy N. Macrophage biology and pathobiology in the evolution of immune responses: a functional analysis. *Pathobiology*. 2001;69(4):179-211.
- Haniffa M, Ginhoux F, Wang XN, et al. Differential rates of replacement of human dermal dendritic cells and macrophages during hematopoietic stem cell transplantation. *J Exp Med*. 2009; 206(2):371-385.
- Kristiansen M, Graversen JH, Jacobsen C, et al. Identification of the haemoglobin scavenger receptor. *Nature*. 2001;409(6817):198-201.
- Fabrick BO, Dijkstra CD, van den Berg TK. The macrophage scavenger receptor CD163. *Immunobiology*. 2005;210(2-4):153-160.
- Moestrup SK, Moller HJ. CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. *Ann Med*. 2004; 36(5):347-354.
- Zaba LC, Fuentes-Duculan J, Steinman RM, Krueger JG, Lowes MA. Normal human dermis contains distinct populations of CD11c⁺BDCA-1⁺ dendritic cells and CD163⁺FXIII⁺ macrophages. *J Clin Invest*. 2007;117(9):2517-2525.
- Przepliora D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. *Bone Marrow Transplant*. 1995;15(6):825-828.
- Inamoto Y, Ito M, Suzuki R, et al. Clinicopathological manifestations and treatment of intestinal transplant-associated microangiopathy. *Bone Marrow Transplant*. 2009;44(1):43-49.
- Nishida T, Hamaguchi M, Hirabayashi N, et al. Intestinal thrombotic microangiopathy after allogeneic bone marrow transplantation: a clinical imitator of acute enteric graft-versus-host disease. *Bone Marrow Transplant*. 2004;33(11): 1143-1150.
- Kennedy MS, Deeg HJ, Storb R, et al. Treatment of acute graft-versus-host disease after allogeneic marrow transplantation: randomized study comparing corticosteroids and cyclosporine. *Am J Med*. 1985;78(6):978-983.
- Ratanatharathorn V, Nash RA, Przepliora D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. *Blood*. 1998;92(7):2303-2314.
- Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. *N Engl J Med*. 1986;314(12):729-735.
- Lin MT, Storer B, Martin PJ, et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. *N Engl J Med*. 2003;349(23):2201-2210.
- Sugimoto K, Murata M, Onizuka M, et al. Decreased risk of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with the 5,10-methylenetetrahydrofolate reductase 677TT genotype. *Int J Hematol*. 2008;87(5):451-458.
- Remberger M, Mattsson J, Hassan Z, et al. Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study. *Bone Marrow Transplant*. 2008;41(4):399-405.
- Lee KH, Choi SJ, Lee JH, et al. Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. *Haematologica*. 2005; 90(7):939-948.
- Patriarca F, Sperotto A, Damiani D, et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. *Haematologica*. 2004; 89(11):1352-1359.
- Couriel D, Saliba R, Hicks K, et al. Tumor necrosis factor- α blockade for the treatment of acute GVHD. *Blood*. 2004;104(3):649-654.
- Oussoren C, Storm G. Role of macrophages in the localisation of liposomes in lymph nodes after subcutaneous administration. *Int J Pharm*. 1999; 183(1):37-41.
- Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. *J Immunol Methods*. 1994;174(1):83-93.
- Liu Q, Hamblin MR. Macrophage-targeted photodynamic therapy: scavenger receptor expression and activation state. *Int J Immunopathol Pharmacol*. 2005;18(3):391-402.
- Demidova TN, Hamblin MR. Macrophage-targeted photodynamic therapy. *Int J Immunopathol Pharmacol*. 2004;17(2):117-126.

Authorship

Contribution: S.N., S.T., M.I., and K.M. designed the research; S.N., S.T., and M.I. analyzed and interpreted the data; S.N. and S.T. performed statistical analysis; and S.N., T.G., A.S., K.W., M.Y., N.I., S.T., M.S., Y.O., M.I., and K.M. collected clinical data and wrote the paper.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Masafumi Ito, Department of Hematology, Japanese Red Cross Nagoya First Hospital, 3-35 Michishita-cho, Nakamura-ku, Nagoya 453-8511, Japan; e-mail: itom@nagoya-1st.jrc.or.jp.

Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients

Katsuto Takenaka · Tetsuya Eto · Koji Nagafuji · Kenjiro Kamezaki · Yayoi Matsuo · Goichi Yoshimoto · Naoki Harada · Maki Yoshida · Hideho Henzan · Ken Takase · Toshihiro Miyamoto · Koichi Akashi · Mine Harada · Takanori Teshima · for Fukuoka Blood and Marrow Transplant Group (FBMTG)

Received: 22 September 2008 / Revised: 26 November 2008 / Accepted: 18 December 2008 / Published online: 17 January 2009
© The Japanese Society of Hematology 2009

Abstract Between March 2007 and January 2008, the safety and efficacy of oral valganciclovir (VGC) preemptive therapy for cytomegalovirus (CMV) infection was evaluated in ten consecutive patients who received allogeneic hematopoietic stem cell transplantation (HSCT). Patients were screened once or twice per week after engraftment using CMV pp65 antigenemia assay. When more than 2 CMV antigen-positive cells per 50,000 leukocytes were detected, preemptive therapy with oral VGC was initiated at a dose of 900 mg twice daily for 3 weeks. Nine patients (90%) completed the 3-week VGC treatment except for one patient who developed febrile neutropenia. There was no other significant toxicity. CMV antigen-positive cells were rapidly decreased in all nine patients and became undetectable by the end of the VGC treatment. None of the patients developed CMV disease. CMV

infection relapsed in four of the ten patients (40%) after the VGC treatment. These observations suggest that preemptive therapy with VGC is effective for preventing CMV disease in allogeneic HSCT patients. Further studies with a large number of patients will be necessary to determine the optimal initial- and maintenance-dose of VGC.

Keywords Allogeneic hematopoietic stem cell transplantation · Cytomegalovirus infection · Preemptive therapy · Valganciclovir

1 Introduction

Despite improvement in the treatment of cytomegalovirus (CMV) infection and CMV disease with ganciclovir (GCV) and/or foscarnet, CMV disease is still a major cause of morbidity and mortality after hematopoietic stem cell transplantation (HSCT) [1–4]. Major risk factors for CMV disease include CMV seropositivity before transplantation, development of graft-versus-host disease (GVHD), unrelated donor transplantation, and T cell depleted transplantation [3, 5–7]. In addition, new transplantation modalities such as nonmyeloablative conditioning regimens consisting of intensive immunosuppression increase the risk of late-onset CMV infection and CMV disease [2, 8]. Therefore, extended prevention of CMV disease may be required, especially for high-risk recipients, not only those within 100 days after HSCT but also those in the later period after HSCT [8–10]. Currently, the prevention of CMV disease involves general prophylaxis and preemptive therapy. Preemptive therapy is based on the early detection of CMV infection by virus surveillance, by monitoring with either CMV antigenemia assay or PCR techniques and followed by immediate treatment with anti-CMV drugs

K. Takenaka (✉) · K. Nagafuji · K. Kamezaki · G. Yoshimoto · N. Harada · K. Akashi · M. Harada
Department of Medicine and Biosystemic Science,
Kyushu University Graduate School of Medical Sciences,
3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
e-mail: takenaka@intmed1.med.kyushu-u.ac.jp

T. Eto · Y. Matsuo · M. Yoshida · H. Henzan · K. Takase
Department of Hematology,
Hamanomachi General Hospital, Fukuoka, Japan

T. Miyamoto · T. Teshima
Center for Cellular and Molecular Medicine,
Kyushu University Hospital, Fukuoka, Japan

M. Harada
Department of Internal Medicine,
National Hospital Organization Omuta National Hospital,
Omuta, Japan

[4, 11–13]. Intravenous GCV (IV-GCV) and/or foscarnet are commonly used for preemptive therapy and are effective for decreasing the incidence of early CMV disease [11, 13, 14]. However, these antiviral treatments are given intravenously and often require hospitalization, as well as high costs and IV-related complications.

Valganciclovir hydrochloride (VGC) is an oral valine-ester GCV prodrug with a tenfold higher bioavailability than oral GCV, and it is rapidly hydrolyzed to GCV after oral administration. VGC and IV-GCV have similar efficacy in the treatment of CMV retinitis in HIV-infected patients and in preemptive CMV treatment in solid organ (heart, renal, and renal-pancreas) transplant patients [15–19]. Recently, several studies have shown the efficacy of VGC for preemptive therapy in allogeneic HSCT patients [20–23]. We evaluated the safety and efficacy of oral VGC as preemptive therapy for CMV reactivation in ten allogeneic HSCT patients.

2 Patients and methods

2.1 Patients

This was a prospective multicenter study with VGC. The study patients were adults who had received an allogeneic bone marrow or peripheral blood stem cell transplant. Patients were eligible when they screened for CMV infection using CMV pp65 antigenemia assay and more than two CMV antigen-positive cells were detected. Patients unable to take oral medication, and those who impaired renal function (serum creatinine level >2.0 mg/dL) were ineligible. Patients, who developed CMV disease, had received antiviral agents other than acyclovir and who developed more than stage 2 gastrointestinal GVHD were also ineligible. Ten consecutive patients who received allogeneic HSCT at Kyushu University Hospital and Hamanomachi General Hospital between March 2007 and January 2008 were included in the study (Table 1). This study was approved by Institutional Review Board of each institute and a written informed consent was obtained from each participating patient.

Eight patients had acute myeloid leukemia, one had myelodysplastic syndrome, and one had non-Hodgkin's lymphoma. The median age of the patients at the time of transplantation was 56 years (range 33–63). They received bone marrow grafts from an HLA-matched sibling donor ($n = 1$), a matched unrelated donor ($n = 8$), or an HLA-1 locus mismatched unrelated donor ($n = 1$). All of the patients were CMV seropositive before transplantation. Nine patients received myeloablative preparative regimens including total body irradiation/cyclophosphamide (Cy) in five patients and busulfan (BU)/Cy in four patients.

Table 1 Patient characteristics

Number of patients	10
Median age, years (range)	56 (33–65)
Diagnosis	
Acute myeloid leukemia	8
Myelodysplastic syndrome	1
Non-Hodgkin's lymphoma	1
Stem cell source	
HLA-identical sibling bone marrow	1
HLA-matched unrelated bone marrow	8
HLA-mismatched unrelated bone marrow	1
CMV serologic status	
Donor + /Recipient +	9
Donor –/Recipient +	1
Preparative regimens	
TBI/Cy	5
Bu/Cy	4
Flu/Bu/TBI	1
GVHD prophylaxis	
Tacrolimus + MTX	9
CSP + MTX	1
Acute GVHD prior to CMV reactivation	
Grade I	1
Grade II	7
Grade III	2
PSL treatment at the time of starting VGC	8

Bu busulfan, *CMV* cytomegalovirus, *CSP* cyclosporine, *Cy* cyclophosphamide, *Flu* fludarabine, *GVHD* graft-versus-host disease, *TBI* total body irradiation, *MTX* methotrexate, *PSL* prednisolone, *VGC* valganciclovir

The remaining patient received a fludarabine-based reduced-intensity conditioning regimen. GVHD prophylaxis consisted of tacrolimus/short-term methotrexate (MTX) ($n = 9$) or cyclosporine/short-term MTX ($n = 1$). Patients who developed grade II–IV acute GVHD were given methylprednisolone (mPSL) or prednisolone (PSL) at a dose of 1 or 2 mg/kg. Acyclovir was administered orally (1,000 mg/day) or intravenously (500 mg/day) from days –7 to 35 as a prophylaxis against herpes simplex infection.

2.2 CMV antigenemia assay

CMV antigenemia assay was determined as previously described [7, 24]. In brief, peripheral blood leukocytes isolated from 3 mL of EDTA-treated blood were applied to slides by centrifugation and fixed with cold acetone. The slides were stained using a direct immunoperoxidase technique that employed the peroxidase-conjugated monoclonal antibody HRP-C7 (Teijin, Tokyo, Japan) against the CMV pp65 antigen. CMV antigen-positive cells were counted under a light microscope and the results were

expressed as the number of CMV antigen-positive cells per 50,000 leukocytes.

2.3 Definition of CMV infection and CMV disease

A positive test for CMV antigenemia was defined as the presence of one or more CMV antigen-positive cells per 50,000 leukocytes. CMV infection was considered in patients with a positive test for CMV antigenemia. CMV disease was diagnosed according to published recommendations [25]. Patients with clinical manifestations of CMV disease, such as interstitial pneumonia and gastroenteritis in the presence of CMV infection, were examined histopathologically and immunochemically from biopsy specimens.

2.4 Preemptive therapy with VGC for CMV infection

Monitoring with CMV antigenemia assay was performed at least once per week after engraftment until day 100 after HSCT and once every other week thereafter. Preemptive therapy with VGC for CMV infection was initiated at the time of the first detection of more than two CMV antigen-positive cells per 50,000 leukocytes. VGC was administered orally at a dose of 900 mg twice daily for 3 weeks. The dose was adjusted for patients with impaired renal function according to the manufacturer's recommendation. Acyclovir for the prophylaxis against herpes simplex infection was discontinued when VGC treatment was started. Supplemental immunoglobulin was administered only when a total IgG level was less than 400 mg/dL.

2.5 Endpoints and definitions

The primary endpoint was the rate of complete response of the VGC preemptive therapy to the CMV infection. The efficacy of VGC was monitored weekly using a CMV antigenemia assay. A complete response was defined as the conversion from positive to negative CMV antigenemia test results at the completion of the treatment. Patients who persistently showed positive test results for CMV antigenemia after 3 weeks of preemptive therapy or developed CMV disease during the period of preemptive therapy were considered a treatment failure.

The secondary endpoints included the safety of preemptive therapy, the incidence of CMV disease during VGC treatment, and the incidence of a recurrent CMV reactivation after the completion of VGC treatment. The patients were monitored with the CMV antigenemia assay for 5 weeks after the completion of the VGC treatment. At least once per week, a safety analysis was conducted. The analysis included the monitoring of blood counts, liver and renal function tests, and documenting other unexpected

side effects. The incidence of CMV disease was evaluated for the entire period of the study. The incidence of recurrent reactivation of CMV infection after the VGC preemptive therapy was based on the conversion from negative CMV antigenemia to positive CMV antigenemia test results with more than two CMV antigen-positive cells per 50,000 leukocytes during the 5-week follow-up period.

3 Results

3.1 CMV infection and VGC preemptive therapy

Forty-seven patients received allogeneic bone marrow/peripheral blood stem cell transplants at these two institutes during the study period. Thirty-one patients showed positive CMV antigenemia test results after transplantation. Ten patients were enrolled into this study, but the remaining 21 patients were not enrolled mostly by their inability to take oral medication. Ten enrolled patients were given preemptive therapy with VGC for CMV infection (Table 1). All patients were CMV seropositive before transplantation, and nine donors were also CMV seropositive. In these patients, more than 2 CMV antigen-positive cells per 50,000 leukocytes were detected after a median of 69 days (range 22–252) following transplantation. The median number of CMV antigen-positive cells at the initiation of VGC therapy was 5 per 50,000 leukocytes (range 3–59). All of the patients developed acute GVHD prior to CMV infection after a median of 23 days (range 11–135). The severity of acute GVHD was grade I in one patient, grade II in seven, and grade III in two. Eight patients received mPSL or PSL for the treatment of acute GVHD. Preemptive therapy with VGC was started within five days after the detection of CMV antigen-positive cells. Nine patients completed 21 days of VGC treatment, whereas one patient failed to complete the therapy because of the development of grade 4 neutropenia and subsequent febrile neutropenia. Patients were followed at least 5 weeks after the completion of VGC preemptive therapy. The median follow-up was day 122 (range 41–355).

3.2 Response to VGC preemptive therapy

All patients showed negative test results for CMV antigenemia within 3 weeks after the initiation of the VGC treatment. In nine patients, CMV antigen-positive cells became negative within 2 weeks (Fig. 1). The remaining patient, who had 60/50,000 CMV antigen-positive cells at the time of initiation of VGC treatment, took 3 weeks to clear CMV antigen-positive cells. None of the patients required other anti-CMV agents. None of the patients developed CMV disease during the preemptive therapy or




Fig. 1 Time course of the number of cytomegalovirus (CMV) antigen-positive cells after valganciclovir treatment. CMV antigenemia was reduced during treatment with valganciclovir. The *box plots* display the median, the 25th and 75th percentiles (*box*), and the smallest and largest values (*longitudinal line*). One patient discontinued valganciclovir on day 18 due to grade 4 neutropenia

in the subsequent 5 weeks after the completion of the VGC treatment.

CMV infection relapsed in four of the ten patients within 3–5 weeks after the completion of the preemptive VGC therapy. These four patients were successfully treated with IV-GCV.

3.3 Toxicity

Nine patients completed a 21-day course of VGC treatment, but one patient discontinued VGC due to grade 4 neutropenia. Due to impaired renal function (serum creatinine level, 1.68 mg/dL), this patient received a reduced VGC dose of 450 mg once per day for the first week. Renal function improved with the reduced dose, and the VGC dosage was increased to 450 mg twice per day in the second week of treatment. However, this patient developed grade 4 neutropenia (absolute neutrophil counts $0.17 \times 10^9/L$) after 17 days of treatment and then developed febrile neutropenia. The VGC was discontinued, and the patient immediately received granulocyte-colony stimulating factor (G-CSF) and antibiotic therapy. Neutrophil counts recovered to more than $1.0 \times 10^9/L$, and neutropenia resolved after five days. Recurrent CMV reactivation was not observed in this patient during the follow-up period. None of the patients developed thrombocytopenia (platelet count $<30 \times 10^9/L$) (Fig. 2).




Fig. 2 Time course of neutrophils and platelets during valganciclovir treatment. Time course of neutrophil (a) and platelet numbers (b) during treatment with valganciclovir. The bar graph displays the median (*horizontal line*), and the smallest and largest values (*longitudinal line*). One patient discontinued valganciclovir on day 18 due to grade 4 neutropenia

Table 2 Adverse events other than hematological toxicities related to valganciclovir

Adverse events	No. of cases
Gastrointestinal	
Diarrhea	Grade 1 1/10
Hepatic	
AST/ALT	Grade 1 3/10

None of the patients experienced renal toxicity during the VGC treatment. Three patients developed grade 1 liver dysfunction, and one patient had grade 1 diarrhea (Table 2). However, none of these complications required discontinuation of the VGC.

4 Discussion

Effective preemptive therapy with IV-GCV reduced the incidence of early CMV disease to 5–10%; however, the risk of late CMV disease beyond day 100 after transplantation has increased over the past few years. Therefore, extended CMV monitoring beyond day 100 is currently recommended, especially in high-risk patients [2, 8]. There is a need for an effective oral anti-CMV drug that can be used for outpatient care. Oral VGC could be a useful alternative to IV-GCV in patients who require preemptive therapy for CMV infection. This study demonstrated the efficacy and safety of preemptive VGC therapy for CMV infection after allogeneic HSCT. There are four published studies that have shown the safety and the efficacy of VGC as preemptive therapy after allogeneic HSCT [20–23]. Although dosage and duration of the drug varied between studies, VGC therapy resulted in a rapid decrease of the viral load in all of the patients. In this study, we administered a dose of 900 mg twice daily for 3 weeks, and corroborated the efficacy and the tolerability of preemptive VGC therapy.

We demonstrated that VGC at a dose of 900 mg twice per day was effective and resulted in a rapid clearance of CMV antigen-positive cells in all patients. No CMV disease developed during the preemptive therapy or the subsequent 5 weeks after the completion of treatment. VGC was well tolerated as 90% of the patients completed the entire treatment course. However, four of the ten patients developed a recurrent CMV reactivation after the discontinuation of VGC treatment, and they were all successfully treated with IV-GCV. Because a guideline for preemptive VGC therapy has not been established for patients that have received allogeneic HSCT, further studies will be necessary to determine the optimal initial- and maintenance-dose of VGC.

We, and four other groups, have obtained good results with VGC starting-doses of 900 mg twice per day [20–23]. This dose was based on observations from previous pharmacokinetics studies in HIV-infected patients and liver transplant recipients. A VGC dose of 900 mg results in an area under the concentration-time curve for GCV similar to that of 5 mg/kg IV-GCV [26, 27], which is the recommended standard dose for preemptive CMV therapy [28, 29]. One of the concerns of using VGC after allogeneic HSCT is the absorption of oral VGC in patients suffering from severe gastrointestinal GVHD. Recently, Einsele et al. [30] conducted a randomized crossover clinical trial of IV-GCV and VGC in patients with or without intestinal GVHD. The results showed that patients without intestinal GVHD who took VGC were exposed to more GCV when compared to those administered IV-GCV. This was also true in patients with grade I and II intestinal GVHD. Thus,

VGC may be as effective even in patients developing a mild form of intestinal GVHD as in patients without intestinal GVHD. However, a higher exposure of VGC may increase the toxicity of the drug, and the absorption of VGC was not evaluated in patients with severe intestinal GVHD. Recently, Candoni et al. [22] examined the efficacy of a lower dose of VGC. Preemptive therapy with 900 mg/day VGC was as effective for clearing CMV antigen-positive cells and preventing CMV disease as the standard dose of 1800 mg/day. These findings suggest that the initial dose of VGC could be reduced to 900 mg/day as preemptive therapy in low-risk patients.

The effective duration for preemptive VGC therapy is currently unclear. In the previous studies, patients received VGC for 2 weeks and then it was either discontinued or continued at a maintenance dose of variable duration dependant upon a negative CMV test result. Different from previous studies, we continued an initial dose of VGC for 3 weeks. The dosage and duration of VGC therapy likely affects the incidence of hematological toxicity such as neutropenia. In a study by Busca et al. [21], in which VGC was administered at a dose of 1,800 mg/day for 2 weeks, followed by 900 mg/day for an additional 2 weeks, 4 of the 15 patients failed to complete the 3-week scheduled therapy due to neutropenia and/or thrombocytopenia. In our study, only one of the ten patients failed to complete treatment. Thus, hematologic toxicity may be a significant problem after a 3 week treatment with VGC.

In our study, four of the ten patients treated with VGC developed recurrent CMV reactivation 3–5 weeks after the discontinuation of VGC. This was somewhat similar to the 10–53% recurrence rates in previous studies [20–23]. Thus, careful monitoring after the completion of VGC therapy is recommended. We continued an initial dose of VGC for 3 weeks. However, when considering hematological toxicity and frequent recurrence of CMV antigenemia, the duration of treatment and/or maintenance should be decided by monitoring CMV.

As previously reported [20–23], we found neutropenia to be the main toxic effect of VGC. One patient, who had impaired renal function before the preemptive therapy that required a dose reduction, discontinued the drug on day 17 due to grade 4 neutropenia. In high-risk patients, especially outpatient should be closely monitored, although any other toxicity profile different from IV-GCV was not observed in this study.

Our study demonstrated that the oral VGC preemptive therapy at a dose of 900 mg daily seemed to be as effective as conventional IV-GCV at a dose of 10 mg/kg daily to clear CMV antigen-positive cells. However, as shown in Fig. 1, CMV antigen-positive cells seem to decrease in numbers much faster after VGC treatment than those observed after standard dose of IV-GCV treatment.

Furthermore, hematological toxicities were considerable. Although pharmacokinetic data was not available in this study, these observations coincide with the previous pharmacokinetic study in HSCT recipients that showed the exposure of GCV after administration of 1800 mg daily VGC was significantly higher compared with 10 mg/kg IV-GCV even in patients without gastrointestinal GVHD [30]. Careful monitoring of neutrophil counts will be useful to improve the safety of VGC in HSCT recipients, especially with reduced renal function. Kanda et al. [14] showed the efficacy of response-oriented preemptive therapy using a low initial dose of IV-GCV that resulted in a successful reduction of the total dose of IV-GCV and decreased hematological toxicities. A lower dose of VGC could be also used as preemptive therapy by close CMV monitoring. Similar studies with a large number of patients will be required to define the optimal treatment schedule for preemptive VGC therapy.

Despite a limited number of patients, our results suggest that oral VGC is an effective alternative to IV-GCV for preemptive therapy to prevent CMV disease in allogeneic HSCT patients. Studies with a larger number of patients will be necessary to assess the efficacy and long-term effect of this preemptive therapy.

References

- Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. *Blood*. 2004;103(6):2003–8. doi:10.1182/blood-2003-10-3616.
- Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. *Biol Blood Marrow Transplant*. 2003;9(9):543–58. doi:10.1016/S1083-8791(03)00287-8.
- Forman SJ, Zaia JA. Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: where do we stand? *Blood*. 1994;83(9):2392–8.
- Ljungman P, Aschan J, Lewensohn-Fuchs I, et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. *Transplantation*. 1998;66(10):1330–4. doi:10.1097/00007890-199811270-00012.
- Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. *J Infect Dis*. 1986;153(3):478–88.
- Miller W, Flynn P, McCullough J, et al. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease. *Blood*. 1986;67(4):1162–7.
- Takenaka K, Gondo H, Tanimoto K, et al. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. The Fukuoka Bone Marrow Transplantation Group. *Bone Marrow Transplant*. 1997;19(3):241–8. doi:10.1038/sj.bmt.1700637.
- Asano-Mori Y, Kanda Y, Oshima K, et al. Clinical features of late cytomegalovirus infection after hematopoietic stem cell transplantation. *Int J Hematol*. 2008;87(3):310–8. doi:10.1007/s12185-008-0051-1.
- Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. *Blood*. 2003;101(2):407–14. doi:10.1182/blood-2002-03-0993.
- Einsele H, Hebart H, Kauffmann-Schneider C, et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. *Bone Marrow Transplant*. 2000;25(7):757–63. doi:10.1038/sj.bmt.1702226.
- Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. *Blood*. 1995;86(7):2815–20.
- Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. *N Engl J Med*. 1991;325(23):1601–7.
- Reusser P, Einsele H, Lee J, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. *Blood*. 2002;99(4):1159–64. doi:10.1182/blood.V99.4.1159.
- Kanda Y, Mineishi S, Saito T, et al. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan. *Bone Marrow Transplant*. 2001;27(4):437–44. doi:10.1038/sj.bmt.1702805.
- Devyatko E, Zuckermann A, Ruzicka M, et al. Pre-emptive treatment with oral valganciclovir in management of CMV infection after cardiac transplantation. *J Heart Lung Transplant*. 2004;23(11):1277–82. doi:10.1016/j.healun.2003.08.034.
- Diaz-Pedroche C, Lumbreras C, Del Valle P, et al. Efficacy and safety of valganciclovir as preemptive therapy for the prevention of cytomegalovirus disease in solid organ transplant recipients. *Transplant Proc*. 2005;37(9):3766–7. doi:10.1016/j.transproceed.2005.10.075.
- Kalpole JS, Schippers EF, Eling Y, Sijpkens YW, de Fijter JW, Kroes AC. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation. *Antivir Ther*. 2005;10(1):119–23.
- Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. *N Engl J Med*. 2002;346(15):1119–26. doi:10.1056/NEJMoa011759.
- Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. *Am J Transplant*. 2004;4(4):611–20. doi:10.1111/j.1600-6143.2004.00382.x.
- Ayala E, Greene J, Sandin R, et al. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant*. 2006;37(9):851–6. doi:10.1038/sj.bmt.1705341.
- Busca A, de Fabritiis P, Ghesetti V, et al. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation. *Transpl Infect Dis*. 2007;9(2):102–7. doi:10.1111/j.1399-3062.2006.00183.x.
- Candoni A, Simeone E, Tiribelli M, Pipan C, Fanin R. What is the optimal dosage of valganciclovir as preemptive therapy for CMV infection in allogeneic hematopoietic SCT? *Bone Marrow Transplant*. 2008;42(3):207–8. doi:10.1038/bmt.2008.98.

23. van der Heiden PL, Kalpoe JS, Barge RM, Willemze R, Kroes AC, Schippers EF. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. *Bone Marrow Transplant.* 2006;37(7):693–8. doi:10.1038/sj.bmt.1705311.

24. Gondo H, Minematsu T, Harada M, et al. Cytomegalovirus (CMV) antigenaemia for rapid diagnosis and monitoring of CMV-associated disease after bone marrow transplantation. *Br J Haematol.* 1994;86(1):130–7. doi:10.1111/j.1365-2141.1994.tb03263.x.

25. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. *Clin Infect Dis.* 2002;34(8):1094–7. doi:10.1086/339329.

26. Brown F, Banken L, Saywell K, Arum I. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. *Clin Pharmacokinet.* 1999;37(2):167–76. doi:10.2165/00003088-199937020-00005.

27. Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. *Antimicrob Agents Chemother.* 2000;44(10):2811–5. doi:10.1128/AAC.44.10.2811-2815.2000.

28. Centers for Disease Control and Prevention IDSoA, American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. *Biol Blood Marrow Transplant.* 2000;6(6a):659–727.

29. Fraser GA, Walker II. Cytomegalovirus prophylaxis and treatment after hematopoietic stem cell transplantation in Canada: a description of current practices and comparison with Centers for Disease Control/Infectious Diseases Society of America/American Society for Blood and Marrow Transplantation guideline recommendations. *Biol Blood Marrow Transplant.* 2004;10(5):287–97. doi:10.1016/j.bbmt.2003.10.007.

30. Einsele H, Reusser P, Bornhauser M, et al. Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. *Blood.* 2006;107(7):3002–8. doi:10.1182/blood-2005-09-3786.

Infectious complications in patients receiving autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases

K. Kohno, K. Nagafuji, H. Tsukamoto, T. Horiuchi, K. Takase, K. Aoki, H. Henzan, K. Kamezaki, K. Takenaka, T. Miyamoto, T. Teshima, M. Harada, K. Akashi. Infectious complications in patients receiving autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases.

Transpl Infect Dis 2009; 11: 318–323. All rights reserved

Abstract: Long-term analysis of infectious complication after high-dose immunosuppressive therapy with CD34-selected autologous hematopoietic stem cell transplantation for patients with severe autoimmune diseases (AD) was performed. Theoretically, CD34 selection can reduce the risk of reinfusion of autoreactive lymphocytes. However, it is also associated with a significant reduction in T cells, natural killer cells, and monocytes, which in turn may compromise immune reconstitution, thereby increasing the risk of infection. Moreover, AD compromises host immunity and causes organ damage resulting in dysfunction of the cutaneous or mucosal barrier. In this study, the incidence rate of infections is reported in 14 patients who underwent high-dose (200 mg/kg) cyclophosphamide therapy followed by reinfusion of CD34-selected autologous peripheral blood stem cells. Bacterial complication occurred in 3 of 14 (21%) patients. Cytomegalovirus reactivation and adenovirus hemorrhagic cystitis were observed in 9 (64%) and 2 (14%) patients, respectively. As for late infectious complications, 7 patients (50%) developed dermatomal varicella zoster virus infection. No infection-related mortality was seen in this case series. Because the risk for infections approaches that seen in allogeneic transplant recipients, infection surveillance, diagnostic workup, and prophylactic strategies similar to those applicable to allogeneic recipients are warranted.

K. Kohno^{1,2}, K. Nagafuji¹, H. Tsukamoto¹, T. Horiuchi¹, K. Takase¹, K. Aoki¹, H. Henzan¹, K. Kamezaki¹, K. Takenaka¹, T. Miyamoto², T. Teshima², M. Harada¹, K. Akashi^{1,2}

¹Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan,

²Center for Cellular and Molecular Medicine, Kyushu University Hospital, Fukuoka, Japan

Key words: Infection; stem cell transplantation; autologous; hematopoietic; CD34-selected; peripheral blood stem cells; autoimmune disease; cytomegalovirus; varicella zoster virus; adenovirus; bacteremia

Correspondence to:

Koji Nagafuji, MD, PhD, Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan

Tel: 81-92-642-5230

Fax: 81-92-642-5247

E-mail: nagafuji@intmed1.med.kyushu-u.ac.jp

Received 23 October 2008, revised 24 December 2008, accepted for publication 4 January 2009

DOI: 10.1111/j.1399-3062.2009.00401.x

Transpl Infect Dis 2009; 11: 318–323

Pilot studies comprising high-dose immunosuppressive therapy followed by transplantation of autologous hematopoietic stem cells (HSC) were conducted to obtain safety and preliminary efficacy data in patients with severe autoimmune diseases (AD) (1–5).

Both unselected and CD34-selected peripheral blood stem cells (PBSC) have been used as sources of HSC (1–5). Theoretically, CD34+ cell selection of PBSC can reduce the possibility of reinfusion of autoreactive lymphocytes. However, the superiority of CD34-selected PBSC over unmanipulated PBSC has not been established. The safety and efficacy of CD34-selected autologous PBSC transplantation (PBSCT) for refractory AD have been investigated at our institute (6).

PBSCT-related complications include regimen-related toxicities and various infections. For the treatment of AD, PBSCT is a more toxic treatment modality than the conventional immunosuppressive therapies. Organ damage due to AD puts the patients at risk of regimen-related toxicities. Thus, careful selection of refractory AD patients for PBSCT is essential to minimize transplant-related mortality.

Infections are major contributors to morbidity and mortality in PBSCT. In hematological malignancies, CD34-selected autologous PBSCT has been reported to increase incidences of opportunistic infections compared with non-CD34-selected autologous PBSCT (7–11). Most AD patients had undergone immunosuppressive therapy, including cyclosporine and corticosteroids, before transplantation. AD

itself compromises host immunity to various infections. Furthermore, AD causes organ damage such as skin ulcers, esophageal dysmotility, and interstitial pneumonia (IP) resulting in dysfunction of the cutaneous or mucosal barrier. Thus, the understanding of infectious complications is important in increasing the safety of CD34-selected autologous PBSC for AD.

Here, we retrospectively analyze infectious complications during the course of CD34-selected autologous PBSC for severe AD.

Materials and methods

Protocol

The protocol of this phase I/II clinical trial (6) was approved by the ethics committee of Kyushu University Hospital. Written informed consent was obtained from all patients.

Patients and eligibility

Patients between 16 and 65 years of age were eligible at the time of pre-transplant evaluation. Patient eligibility depended on the diagnosis of AD, as previously described (6).

PBSC mobilization and CD34⁺ cell selection

PBSC were mobilized during hematological recovery after administration of cyclophosphamide (CY) (2 g/m²/day) for 2 days, followed by a recombinant human granulocyte-colony stimulating factor (G-CSF, filgrastim; Kirin Brewery, Tokyo, Japan) at a dosage of 2 µg/kg/day. After collecting PBSC to obtain 2 × 10⁶ CD34⁺ cells/kg or more by apheresis, CD34⁺ cells were positively selected using immunomagnetic beads with an anti-CD34 monoclonal antibody (CliniMACS, Miltenyi Biotec, Cologne, Germany).

Autologous PBSC and supportive care

Patients were kept in HEPA-filtered rooms until engraftment. For pre-transplant conditioning, high-dose CY (50 mg/kg/day) was administered for 4 days, from days -5 to -2. Frozen-thawed CD34-selected PBSC were infused on day 0. All immunosuppressive and disease-modifying agents were discontinued upon HSC procurement, except systemic corticosteroids, which were tapered to a relatively low dose (5–15 mg of prednisolone/day) over 2–6 months after PBSC. Acyclovir (intravenous 250 mg/day, from days 1 to 18), ciprofloxacin (by mouth [PO] 600 mg/

day, from days -7 to 14), fluconazole (PO 200 mg/day, from days -7 to 30), and trimethoprim-sulfamethoxazole (TMP-SMX) (each 1920 mg/day; from days -14 to -2, and twice a week from days 30 to 180, respectively) were prophylactically administered, as previously described (6). Neutropenic fever was treated with intravenous administration of broad-spectrum cephalosporins according to the guidelines for the use of antimicrobial agents in neutropenic patients (12). After engraftment, weekly monitoring of cytomegalovirus (CMV) pp65 antigenemia was conducted until day 100 after transplant (13). If CMV antigenemia was detected, preemptive therapy was initiated with ganciclovir.

Diagnosis and definition of infections

The day of onset of infection was defined as the day the diagnostic test was performed.

Bacterial infections were categorized as bacteremias and site-specific infections (14). Varicella zoster virus (VZV) infections were defined as typical cutaneous vesicular lesions. CMV infection and disease were defined as previously described (13, 15). In brief, CMV infection was defined as isolation of the CMV virus or detection of the viral proteins or nucleic acids in body fluid or tissue specimen. CMV disease is defined by the presence of organ-specific signs and/or symptoms with the detection of CMV in test specimens (e.g., bronchoalveolar lavage in the lungs or biopsy samples in other organs). CMV infection with unexplained fever for at least 2 days within a 4-day period and the presence of neutropenia or thrombocytopenia is considered CMV syndrome. Hemorrhagic cystitis (HC) due to adenoviruses (AdV) was diagnosed when AdV were detected by either viral culture or polymerase chain reaction in macroscopic hematuria with clinical signs of cystitis. To exclude regimen-related HC, patients with *de novo* hematuria at least 10 days after HSC transplantation (HSCT) and no tendency toward generalized bleeding or bacteriuria were considered to have AdV HC (16). Fungal infection was defined by proven or probable invasive fungal infection (17) and clinical or radiological manifestation along with positive microbiological tests.

Results

Patients

Fourteen patients (4 males, 10 females) with a median age of 54 years (range 21–63 years) were examined (Table 1). Patients No. 1–11 were diagnosed as diffuse systemic sclerosis (SSc). Patient No. 1 was suffering from systemic lupus er-

Clinical characteristics of the autoimmune patients receiving CD34-selected transplant

Patient number	Disease	Age (years)	Sex	Complication	Previous therapies	Follow up (months) ¹
1	SSc/SLE	54	F	IP, digital ulcer	DEX, IVCY	72
2	SSc	55	M	IP, digital ulcer	PSL, IVCY	65
3	SSc	58	M	IP	PSL, IVCY	61
4	SSc	54	F	IP	PSL, IVCY	58
5	SSc	53	F	IP	PSL	56
6	SSc	49	F	IP	m-PSL, CsA, IVCY	52
7	SSc	33	F	IP	—	21
8	SSc	63	F	IP	PSL	36
9	SSc	61	F	IP	PSL, CsA	31
10	SSc	44	F	IP	PSL, IVCY	27
11	SSc	52	M	IP, digital ulcer	PSL, CsA, IVCY	23
12	DM	54	F	IP	PSL pulse, CsA, IVCY	70
13	DM	44	F	IP, skin ulcer	PSL pulse, CsA	12
14	WG	21	M	Exophthalmos	PSL pulse, IVCY	55

¹After transplantation.
SSc, systemic sclerosis; SLE, systemic lupus erythematosus; IP, interstitial pneumonia; DEX, dexamethasone; IVCY, intravenous cyclophosphamide; PSL, prednisolone; m-PSL, methyl prednisolone; CsA, cyclosporine; DM, dermatomyositis; WG, Wegener's granulomatosis.

Table 1

rythematosus (SLE) for 22 years and SSc for 2 years. Although SLE was inactive, she had progressive IP and severe digital ulcers due to SSc. Patients No. 2–11 (SSc) and 12 and 13 (dermatomyositis) developed IP, which did not respond to immunosuppressive agents. Patients No. 3–6, 8, 9, and 11 showed severe skin sclerosis. Patient No. 3 had been in complete remission from non-Hodgkin's lymphoma for 1 year and was considered eligible. Patient No. 14 (Wegener's granulomatosis) presented with severe exophthalmos due to granuloma formation (18 mm in diameter) in the upper lateral region of the left orbit affecting the superior rectus muscle. He needed monthly steroid pulse therapy to prevent further growth of the granuloma. The Eastern Cooperative Oncology Group performance status (18) was <3 in all patients. CY and cyclosporine were administered to 9 patients and 5 patients, respectively. All patients, except Patient No. 7, were treated with corticosteroids. The median follow-up duration was 53.5 months after transplant (range 8–72 months).

Results are reported as of March 2008.

Infections

Bacterial

Nine of 14 patients developed febrile neutropenia at a median of 6 (0–9) days after PBSCT (Table 2). Among these, Patients No. 6 and 11 revealed *Streptococcus mitis* bacter-

emia on days 8 and 9 after PBSCT, respectively. Both were empirically treated with broad-spectrum cephalosporins. Vancomycin was added when the blood culture was reported positive. Patient No. 12 developed high-grade fever without signs of local infection on day 119 post PBSCT, and a blood culture turned out to be positive for *Listeria monocytogenes*. Empirical therapy was initiated with broad-spectrum cephalosporin but switched to penicillin/ β -lactamase inhibitor after detection of the microbe. All patients responded to the therapy, and no fatal complications occurred.

Patient No. 14 developed *Mycobacterium gordonae* pneumonia 1343 days after PBSCT. However, he was on anti-tumor necrosis factor (TNF) antibody therapy because of the relapse at that time; thus the case is omitted from this study.

Viral

CMV. Nine of 14 patients developed CMV antigenemia at a median of 28 days (range 10–60 days) after PBSCT. All patients who developed CMV infection were seropositive for CMV antibody before PBSCT, and this was considered as reactivation. Patients were preemptively treated with ganciclovir (5 mg/kg twice a day) and none developed CMV disease. High levels of antigenemia were detected in Patients No. 1 and 6. With their clinical symptoms, these patients were considered to have CMV syndrome. Foscarnet

was administered to Patient No. 12 because CMV antigenemia persisted despite ganciclovir therapy.

VZV. Seven of 14 patients developed VZV infection at a median of 409 days (range 351–1263 days) after PBSCT. All patients were treated with either oral valacyclovir or intravenous acyclovir promptly after diagnosis. All patients had dermatomal disease, and no dissemination was observed.

AdV. Patients No. 1 and 6 developed AdV HC on days 64 and 33, respectively. Cidofovir was administered in both patients.

Fungal

No fungal infection was observed in this case series.

Discussion

We present a long-term analysis of infectious complications in AD patients who had undergone CD34-selected autologous PBSCT.

Bacterial infections were observed in 3 patients. Despite the increased frequency of isolation of viridans streptococci from the blood of neutropenic patients (19, 20), bacteremia from *S. mitis* was observed in only 2 patients in the present

study. The incidence of streptococcal bacteremia (2/14; 14%) was the same as that reported in other studies (16–31%) (21, 22). Although antibacterial prophylaxis was undertaken with ciprofloxacin (23), the susceptibility of the pathogen to penicillin was intermediate in both cases; hence, vancomycin was added to the treatment regimen. *L. monocytogenes* infection in HSCT is rare (24) because TMP-SMX, traditionally used for prophylaxis, is active against the microbe. However, the patient did not take TMP-SMX when she developed *L. monocytogenes* bacteremia. As TMP-SMX is effective not only in prophylaxis for *Pneumocystis jirovecii* pneumonia but also against *Listeria*, *Nocardia*, and *Toxoplasma*, its prophylactic administration is mandatory.

CMV reactivation has been reported to be uncommon in unselected autologous PBSCT (25–27). However, 64% of our patients (9/14) became positive for CMV antigenemia after PBSCT and were treated with ganciclovir. Although no patient developed CMV disease, the level of antigenemia in 2 patients was so high that they might have developed CMV disease without monitoring and preemptive therapy. Although it is still not clear whether CD34 selection of autograft itself is a risk for CMV infection (7, 28), this proportion of CMV reactivation is comparable to that of CD34-selected autologous HSCT for hematological malignancies, or allogeneic HSCT (13). Thus, we consider CMV monitoring necessary in AD patients undergoing CD34-selected autologous PBSCT.

Infectious complications in autoimmune patients receiving CD34-selected transplant

Patient number	FN (days)	Bacterial infection (days)	CMV Ab	CMV (days)	VZV (days)	Others (days)
1	5	—	+	38	1263	AdV cystitis (64)
2	—	—	+	—	—	—
3	—	—	+	10	351	—
4	—	—	+	24	418	—
5	—	—	+	—	409	—
6	7	<i>Streptococcus mitis</i> (8)	+	33	—	AdV cystitis (31)
7	0	—	—	—	—	—
8	1	—	+	—	—	—
9	5	—	+	22	374	—
10	—	—	+	60	427	—
11	8	<i>Streptococcus mitis</i> (9)	+	28	—	—
12	5	<i>Listeria monocytogenes</i> (119)	+	22	358	—
13	9	—	+	—	—	—
14	9	—	+	—	—	—

FN, febrile neutropenia; days, days after hematopoietic stem cell transplantation; CMV, cytomegalovirus infection; Ab, antibody VZV, varicella zoster virus infection; AdV, adenovirus.

Table 2

AdV HC developed in 2 of 14 patients (14%). The incidence of AdV infection in the autologous HSCT is reported to be 1% (29), and HC is a rare development. T-cell depletion and lymphopenia are the risk factors (30, 31) for AdV disease in adults, and severe lymphopenia was seen in both the patients (139 and 318/ μ L, respectively). They were successfully treated with cidofovir (16).

Regarding late infectious complications, 50% of the patients (7/14) developed VZV infection at a median of 409 days (range 351–1263 days) after PBSCT. Delayed recovery of CD4 + T cell (32, 33) and increased incidences of the VZV infections (8) have been reported in CD34-selected transplantation. In addition to CD34 selection of auto-graft, low-dose steroids were continued after PBSCT in our study. Delayed CD4 + T-cell recovery along with high incidence of late infection were both observed. We used prophylactic acyclovir from days 1 to 35 and did not use long-term low-dose acyclovir prophylaxis (25, 34, 35).

Data are conflicting whether CD34-selected PBSCT for hematologic malignancies and breast cancer cause increased incidence of infections compared with non-CD34-selected PBSCT. In this study, underlying AD itself, prolonged immunosuppressive therapy before PBSCT, CD34 selection of the auto-graft, and low-dose systemic steroid administration after the PBSCT might contribute to the high incidence of infectious complications.

In conclusion, our findings confirm a very high incidence of infectious complications after CD34-selected autologous PBSCT for AD. Because the risk for infections approaches that seen in allogeneic transplant recipients, infection surveillance, diagnostic workup, and prevention strategies similar to those applicable to allogeneic recipients are recommended.

References

- Burt RK, Traynor A, Ramsey-Goldman R. Hematopoietic stem-cell transplantation for systemic lupus erythematosus. *N Engl J Med* 1997; 337 (24): 1777–1778.
- Traynor AE, Schroeder J, Rosa RM, et al. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study. *Lancet* 2000; 356 (9231): 701–707.
- van Laar JM, Farge D, Tyndall A. Autologous Stem cell Transplantation International Scleroderma (ASTIS) trial: hope on the horizon for patients with severe systemic sclerosis. *Ann Rheum Dis* 2005; 64: 1515.
- Nash RA, McSweeney PA, Crofford LJ, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. *Blood* 2007; 110 (4): 1388–1396.
- Oyama Y, Barr WG, Statkute L, et al. Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis. *Bone Marrow Transplant* 2007; 40: 549–555.
- Tsukamoto H, Nagafuji K, Horiuchi T, et al. A phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease. *Ann Rheum Dis* 2006; 65 (4): 508–514.
- Holmberg LA, Boeckh M, Hooper H, et al. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. *Blood* 1999; 94 (12): 4029–4035.
- Crippa F, Holmberg L, Carter RA, et al. Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. *Biol Blood Marrow Transplant* 2002; 8 (5): 281–289.
- Miyamoto T, Gondo H, Miyoshi Y, et al. Early viral complications following CD34-selected autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. *Br J Haematol* 1998; 100 (2): 348–350.
- Witzens-Harig M, Heilmann C, Hensel M, et al. Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34 + -selected peripheral blood progenitor cells. *Stem Cells* 2007; 25 (1): 228–235.
- Lin PC, Lee MY, Lin JT, Hsiao LT, Chen PM, Chiou TJ. Virus reactivation in high-risk non-Hodgkin's lymphoma patients after autologous CD34(+)-selected peripheral blood progenitor cell transplantation. *Int J Hematol* 2008; 87 (4): 434–439.
- Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. *Clin Infect Dis* 2002; 34: 730–751.
- Takenaka K, Gondo H, Tanimoto K, et al. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. The Fukuoka Bone Marrow Transplantation Group. *Bone Marrow Transplant* 1997; 19 (3): 241–248.
- Narimatsu H, Matsumura T, Kami M, et al. Bloodstream infection after umbilical cord blood transplantation using reduced-intensity stem cell transplantation for adult patients. *Biol Blood Marrow Transplant* 2005; 11: 429–436.
- Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. *Clin Infect Dis* 2002; 34 (8): 1094–1097.
- Nagafuji K, Aoki K, Henzan H, et al. Cidofovir for treating adenoviral hemorrhagic cystitis in hematopoietic stem cell transplant recipients. *Bone Marrow Transplant* 2004; 34 (10): 909–914.
- Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. *Clin Infect Dis* 2002; 34 (1): 7–14.
- Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol* 1982; 5 (6): 649–655.
- Classen DC, Burke JP, Ford CD, et al. *Streptococcus mitis* sepsis in bone marrow transplant patients receiving oral antimicrobial prophylaxis. *Am J Med* 1990; 89: 441–446.
- Collin BA, Leather HL, Wingard JR, Ramphal R. Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. *Clin Infect Dis* 2001; 33 (7): 947–953.
- Bilgrami S, Feingold JM, Dorsky D, Edwards RL, Clive J, Tutschka PJ. *Streptococcus viridans* bacteremia following autologous peripheral blood stem cell transplantation. *Bone Marrow Transplant* 1998; 21 (6): 591–595.
- Razonable RR, Litzow MR, Khaliq Y, Piper KE, Rouse MS, Patel R. Bacteremia due to viridans group Streptococci with diminished susceptibility to levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. *Clin Infect Dis* 2002; 34 (11): 1469–1474.

23. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. *Ann Intern Med* 2005; 142 (12, Part 1): 979–995.
24. Radice C, Munoz V, Castellares C, et al. *Listeria monocytogenes* meningitis in two allogeneic hematopoietic stem cell transplant recipients. *Leuk Lymphoma* 2006; 47 (8): 1701–1703.
25. Sullivan KM, Dykewicz CA, Longworth DL, et al. Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. *Hematology Am Soc Hematol Educ Program* 2001; 392–421.
26. Bilgrami S, Aslanzadeh J, Feingold JM, et al. Cytomegalovirus viremia, viruria and disease after autologous peripheral blood stem cell transplantation: no need for surveillance. *Bone Marrow Transplant* 1999; 24: 69–73.
27. Nagafuji K, Eto T, Hayashi S, Tokunaga Y, Gondo H, Niho Y. Fatal cytomegalovirus interstitial pneumonia following autologous peripheral blood stem cell transplantation. Fukuoka Bone Marrow Transplantation Group. *Bone Marrow Transplant* 1998; 21 (3): 301–303.
28. Frere P, Pereira M, Fillet G, Beguin Y. Infections after CD34-selected or unmanipulated autologous hematopoietic stem cell transplantation. *Eur J Haematol* 2006; 76 (2): 102–108.
29. La Rosa AM, Champlin RE, Mirza N, et al. Adenovirus infections in adult recipients of blood and marrow transplants. *Clin Infect Dis* 2001; 32 (6): 871–876.
30. Chakrabarti S, Mautner V, Osman H, et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. *Blood* 2002; 100 (5): 1619–1627.
31. Symeonidis N, Jakubowski A, Pierre-Louis S, et al. Invasive adenoviral infections in T-cell-depleted allogeneic hematopoietic stem cell transplantation: high mortality in the era of cidofovir. *Transpl Infect Dis* 2007; 9 (2): 108–113.
32. Takeshima M, Takamatsu H, Iida M, Mochizuki Y, Okumura H, Yoshida T. Frequent viral infections and delayed CD4 + cell recovery following CD34 + cell-selected autologous peripheral blood stem cell transplantation. *Int J Hematol* 1999; 70 (3): 193–199.
33. Moore J, Brooks P, Milliken S, et al. A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis. *Arthritis Rheum* 2002; 46 (9): 2301–2309.
34. Kanda Y, Mineishi S, Saito T, et al. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2001; 28 (7): 689–692.
35. Asano-Mori Y, Kanda Y, Oshima K, et al. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. *Am J Hematol* 2008; 83 (6): 472–476.

Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease

Takanori Teshima · Koji Nagafuji · Hideho Henzan · Koichi Miyamura · Ken Takase · Michihiro Hidaka · Toshihiro Miyamoto · Katsuto Takenaka · Koichi Akashi · Mine Harada

Received: 15 April 2009 / Revised: 23 May 2009 / Accepted: 3 June 2009 / Published online: 20 June 2009
© The Japanese Society of Hematology 2009

Abstract We prospectively evaluated the safety and efficacy of the anti-CD20 chimeric monoclonal antibody rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation. Seven patients were treated with 375 mg/m² rituximab weekly for 4 consecutive weeks. Rituximab was well tolerated with no severe toxicity observed during treatment. At 1 year, 3 patients showed a partial response to rituximab therapy, 3 had stable disease, and 1 had progressive disease. Rituximab allowed a reduction in the dose of steroids in 4 patients. Responsive manifestations included mild to moderate skin and oral lesions, and immune hemolytic

anemia, and thrombocytopenia. Severe manifestations involving the skin, fascia, and eye did not respond to treatment. These observations suggest that rituximab therapy may be effective for select patients with corticosteroid-refractory chronic GVHD that is not advanced.

Keywords Rituximab · Chronic GVHD · Corticosteroids · Allogeneic transplantation

1 Introduction

Chronic graft-versus-host disease (GVHD) remains to be the major cause of late morbidity and mortality, and has a significant effect on the functional status and quality of life in long-term survivors after allogeneic hematopoietic cell transplantation (HSCT). Chronic GVHD is a pleiomorphic syndrome with highly variable clinical manifestations, involving the skin, liver, eyes, mouth, esophagus, lung, serosal surfaces, lower gastrointestinal tract, female genitalia, and fascia [1, 2]. Corticosteroids in addition to the continuous administration of a calcineurin inhibitor are the standard treatment for chronic GVHD. The prognosis of patients with corticosteroid-refractory chronic GVHD is extremely poor, and there is no standard treatment for these patients [1, 3].

Although the biological mechanisms leading to chronic GVHD are not well understood compared with those leading to acute GVHD, multiple cellular and humoral mechanisms are likely to be involved in chronic GVHD [4, 5]. Much evidence suggest that B cells and humoral immunity are likely to play a role in the pathogenesis of chronic GVHD; the B cell compartment paradoxically shows simultaneous B lymphocytopenia and B cell hyper-reactivity manifested by the production of autoantibodies.

T. Teshima (✉) · T. Miyamoto · K. Akashi
Center for Cellular and Molecular Medicine,
Kyushu University Graduate School of Medical Science,
3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
e-mail: tteshima@cancer.med.kyushu-u.ac.jp

K. Nagafuji · T. Miyamoto · K. Takenaka ·
K. Akashi · M. Harada
Department of Medicine and Biosystemic Science,
Kyushu University Graduate School of Medical Science,
3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan

H. Henzan · K. Takase
Department of Hematology,
Hamanomachi General Hospital, Fukuoka, Japan

K. Miyamura
Department of Hematology,
Japanese Red Cross Nagoya Daiichi Hospital,
Nagoya, Japan

M. Hidaka
Department of Internal Medicine, National Hospital
Organization Kumamoto Medical Center, Kumamoto, Japan

CD86 expression is highly upregulated in B cells upon stimulation with toll-like receptor 9 in patients with chronic GVHD, as compared to that in controls [6]. Alloantibodies specific for recipient minor histocompatibility antigens have been detected in patients with chronic GVHD, usually 4–6 months after transplantation [7, 8]. Patients with antibodies to recipient minor histocompatibility antigens also have T cells specific for the same antigens [9]. A more direct role of B cells has been suggested by experiments showing that the depletion of donor B cells can protect mice from chronic GVHD [10].

Rituximab is a chimeric mouse/human anti-CD20 monoclonal antibody. It binds with high affinity to CD20⁺ cells and specifically depletes B cells in vivo. Several phase II studies and case series studies have suggested that rituximab may be effective in the treatment of chronic GVHD [11–17]. Such beneficial effects of B cell depletion by rituximab further emphasize a potential pathogenic role of B cells in the development of chronic GVHD. However, the organ-specific responses observed between studies are substantially different, possible, in part, because previous retrospective studies involved patients who were heavily treated with different types of immunosuppressive therapy.

Ethnicity is associated with the incidence and severity of GVHD [18]. Japanese that have remained geographically isolated for significant periods of time are likely to have less genetic diversity than other ethnic populations experiencing recent and multiple immigrations. Japanese patients receiving allogeneic HSCT have a lower incidence of acute and chronic GVHD compared with patients in Western countries [19–22]. Furthermore, immunosuppressants other than calcineurin inhibitors and corticosteroids are rarely used to prevent and treat GVHD in Japan because they have not been approved for use. Thus, Japanese patients with chronic GVHD might represent a more homogeneous population in terms of genetic background and prior therapies. Here, we prospectively evaluated the safety and efficacy of rituximab in the treatment of corticosteroid-refractory chronic GVHD in Japanese patients undergoing allogeneic HSCT.

2 Patients and methods

2.1 Patients

An open-labeled and early phase II study of rituximab therapy for corticosteroid-refractory chronic GVHD was conducted. The primary objective was to determine the safety, toxicity, and efficacy of 4 courses of rituximab therapy. Eligible subjects had extensive chronic GVHD, which had shown resistance to prednisolone (PSL) at doses greater than 0.5 mg/kg for 30 days within the previous

12 months, who were receiving a stable dose of cyclosporine (CSP) or tacrolimus (TAC). The patients excluded from the study had a previous history of HSCT, an uncontrolled infection, were carriers of hepatitis B or C viruses, and younger than 18 years. This study was approved by the Institutional Review Board of each participating institute, according to the Declaration of Helsinki, and written informed consent was obtained from each participating patient.

2.2 Rituximab therapy

The patients were premedicated with acetaminophen and diphenhydramine, and then 375 mg/m² rituximab was intravenously administered weekly for 4 weeks. The initial rate of infusion was 25 mg/h, which was increased to 100 mg/h if there was no reaction to the infusion. During 4 courses of treatment, all patients were required to receive a stable dose of immunosuppressive agents. Following 4 courses of rituximab therapy, decisions regarding the tapering of the dose of immunosuppressive medications were prepared by the transplant physician. The recommended sequence was the withdrawal of corticosteroids and then the withdrawal of the calcineurin inhibitors based on the resolution of chronic GVHD.

2.3 Study evaluation

The diagnosis of chronic GVHD required the presence of at least one diagnostic clinical sign of chronic GVHD or diagnostic manifestation confirmed histologically or by other relevant tests in the absence of acute characteristics of GVHD [2]. The disease was classified as limited or extensive and as de novo, quiescent, or progressive GVHD [1, 23]. Chronic GVHD was staged and graded according to National Institute of Health consensus criteria [2]. The global assessment of the severity of chronic GVHD was derived by combining organ- and site-specific scores. Each organ or site was scored according to a 4-point scale (0–3), with 0 representing no involvement and 3 representing severe impairment. In addition, performance status (PS) was evaluated on this 4-point scale. For thrombocytopenia, a score of 0 was defined as platelets $\geq 140 \times 10^9/l$, 1 as platelets $\geq 100 \times 10^9/l$, 2 as platelets $\geq 50 \times 10^9/l$, and 3 as platelets $< 50 \times 10^9/l$. For autoimmune hemolytic anemia (AIHA), a score of 0 was defined as hemoglobin ≥ 12 g/dl and a negative Coombs test result. Scores of 1, 2, and 3 were defined as hemoglobin ≥ 10 , ≥ 7 , and < 7 g/dl, respectively. A post-treatment evaluation was performed every week until 6 weeks and then 2, 3, 4, 6, and 12 months thereafter, which included an assessment of the severity of chronic GVHD in each organ or tissue and a safety analysis. The analysis included the monitoring of

blood counts and liver and renal function test results and documenting unexpected side effects. The severity of adverse events attributable to rituximab was evaluated on the basis of the Common Terminology Criteria for Adverse Events, version 3.0. The therapeutic response was assessed 1 year after the initiation of the study, and was defined as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD). CR was defined as the resolution of all symptoms and signs of chronic GVHD. PR was defined as a partial improvement in scores of ≥ 2 for at least one organ with no progression in any other organs and no requirement of additional systemic immunosuppressive therapy for chronic GVHD. SD was defined as no change in score and no requirement of additional systemic therapy. PD was defined as the objective worsening of the disease or the need for dose escalation of immunosuppressive agents or additional systemic treatment. Statistical analysis was performed using an unpaired 2-tailed *t* test.

3 Results

3.1 Patient characteristics

Seven patients (5 men and 2 women; median age 48 years, age range 24–55 years) were enrolled in this study between April 2006 and March 2007. The patients' characteristics are summarized in Table 1. All patients had extensive and corticosteroid-refractory chronic GVHD after allogeneic HSCT. The diseases for which transplantation was performed were as follows: acute myelogenous leukemia (AML, $n = 3$), chronic myelogenous leukemia (CML, $n = 2$), acute lymphoblastic leukemia (ALL, $n = 1$), and myelodysplastic syndrome (MDS, $n = 1$). Four patients underwent bone marrow transplantation (BMT) from a human leukocyte antigen (HLA)-matched or HLA-DR-mismatched unrelated donor, and 3 underwent peripheral blood stem cell transplantation (PBSCT) from an HLA-matched sibling donor. Myeloablative conditioning regimens were used in 5 patients, whereas fludarabine-based reduced-intensity conditioning regimens were used in 2. GVHD prophylaxis consisted of CSP and short-term methotrexate (MTX) ($n = 4$), TAC and short-term MTX ($n = 2$), or TAC alone ($n = 1$). All patients developed acute GVHD (grade II in 6 patients and grade I in 1 patient), which was successfully treated with 1–2 mg/kg of methylprednisolone (mPSL) or PSL and subsequently developed into quiescent and extensive chronic GVHD. On the basis of the global staging system [2], 4 patients had "severe" chronic GVHD, and 3 had "moderate" disease. The median time from transplantation to study enrollment was 42 months (range 19–112 months). The median time

Table 1 Patients' characteristics

UPN	Age/sex	Diagnosis	Donors	HLA	Stem cell source	GVHD prophylaxis	Type of onset	Prior therapy	Interval from transplantation to rituximab (months)	Interval from onset of chronic GVHD to rituximab (months)
1	24/F	CML	Sibling	Identical	PBSC	CSP+MTX	Quiescent	PSL, CSP	19	8
2	39/M	MDS	Unrelated	Identical	BM	TAC+MTX	Quiescent	PSL, pulse mPSL, CSP, TAC	42	39
3	48/M	AML	Unrelated	Identical	BM	TAC	Quiescent	PSL, TAC	46	43
4	51/M	CML	Unrelated	DR mismatch	BM	TAC+MTX	Quiescent	PSL, CSP, TAC	112	109
5	55/F	AML	Unrelated	Identical	BM	CSP+MTX	Quiescent	PSL, CSP	34	30
6	55/M	AML	Sibling	Identical	PBSC	CSP+MTX	Quiescent	PSL, CSP	47	37
7	29/M	ALL	Sibling	Identical	PBSC	CSP+MTX	Quiescent	PSL, mPSL, CSP	27	25

from the onset of chronic GVHD to study enrollment was 37 months (range 8–109 months). In all patients, prior therapy for chronic GVHD was a combination of corticosteroid and CSP or TAC. None of the patients received other immunosuppressive medications. The intervals between dose escalations of corticosteroids and rituximab administration were at a minimum of 1 month. All subjects were followed for 1 year after the initiation of rituximab therapy.

3.2 Toxicity

All patients completed a 4-week course of rituximab treatment. Only one patient developed grade 2 allergic toxicity, i.e., an infusion reaction after the first dose of rituximab. None of the patients developed grade 3 or 4 adverse events attributable to rituximab during the 4-week treatment. Later adverse events, occurring within 1 year of the initiation of therapy, included the following: grade 3 bacterial infection that required intravenous administration of cefepim in 1 patient at 2 months, grade 2 herpes simplex virus infection that required treatment with valaciclovir in 1 patient at 4 months, grade 1 hepatic injury in 1, and grade 2 renal damage in 1. These adverse events were likely related to other drugs that were used or to pronounced immune suppression related to transplantation and chronic GVHD.

3.3 Efficacy

All patients were evaluable for their response to rituximab therapy at 1 year after the study initiation (Table 2). Unique patient number (UPN) 1 developed skin sclerosis, which was initially treated with 0.5 mg/kg of PSL. Six months later, her chronic GVHD progressed to “severe” skin sclerosis and contracture. Chronic GVHD initially responded to rituximab with an improvement of symptoms, leading to successful tapering of PSL by 67% over 6 weeks. However, sclerosis progressed thereafter, and the PSL dose was increased. The PSL dose was subsequently reduced again by 67% of the initial dose at 1 year, at which time the global staging and organ-specific scores were unchanged as compared to those before rituximab therapy. The overall response at 1 year was classified with PD because of the need for an escalation in the dose of PSL. UPN 2 developed chronic GVHD in the skin and mouth, which was initially responded to 250 mg of mPSL. Skin and oral lesions were exacerbated 10 months before enrollment to this study. CSP was replaced with TAC and PSL dose was increased to 0.5 mg/kg, but chronic GVHD progressed to “moderate” cutaneous and oral disease. Rituximab therapy was started, but was not effective. However, the disease was

stable during the study period without the need for an escalation in dose of CSP and PSL.

UPN 3 developed extensive chronic GVHD, including cutaneous, oral, and hepatic lesions, and autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia. This patient had steroid-induced diabetes mellitus and a history of tuberculosis. The patient was initially treated with 1 mg/kg of PSL. Three months before study enrollment, PSL was increased to 0.8 mg/kg, which was maintained until study entry according to the past history of exacerbation with less doses of PSL. Rituximab therapy improved “severe” GVHD to “moderate” GVHD, and allowed an 82% reduction in the dose of PSL within 1 year of the study.

UPN 4 had a 9-year history of chronic GVHD. The most severe manifestation was slowly progressive sclerodermatous lesions in the cervical and lower facial skin and fascia, which resulted in severe flexion and rotation contracture and difficulty in mouth opening and swallowing. Rituximab therapy failed to improve these manifestations, but the disease did not progress during the study period with stable doses of CSP and PSL. However, the patient required additional immunosuppressive therapy with high-dose cyclophosphamide 17 months after rituximab therapy and died of bacterial pneumonia, which developed during cyclophosphamide-induced neutropenia.

UPN 5 had “severe” sclerodermatous skin lesions in both the upper and lower extremities. The patient also had recurrent pleural effusion and ascites and a motility disorder of the intestine. The patient was initially treated with 0.5 mg/kg of PSL. Nine months before study enrollment, the disease was deteriorated and PSL dose was increased to 0.5 mg/kg, which was discontinued before rituximab therapy because of a lack of improvement and steroid intolerance. Rituximab therapy temporally improved serositis and diarrhea, but global staging and organ-specific scores were unchanged at 1 year. The patient died of bacterial pneumonia 19 months after the initiation of rituximab therapy.

UPN 6 developed corticosteroid-refractory chronic GVHD in the skin, mouth, eyes, and muscles. Rituximab improved these symptoms, and the patient was able to discontinue PSL by 1 year. Interestingly, the patient developed conductive hearing loss due to inflammation in the bilateral middle ear at the onset of chronic GVHD. The patient recovered dramatically from deafness after the fourth dose of rituximab therapy. UPN 7 developed cutaneous chronic GVHD and treated with PSL. The disease was progressed to sclerodermatous skin disease and the patient was started on 2 mg/kg of mPSL, which was reduced due to a lack of improvement and the patient entered to this study. Sclerodermatous skin lesion improved slowly after rituximab therapy and disappeared

Table 2 Response to rituximab therapy

UPN	Pretreatment			2 months			1 year			Global response	Follow-up
	Global staging	Organ/manifestation	Score	Global staging	Score	% PSL reduction	Global staging	Score	% PSL reduction		
1	Severe	PS	1	Severe	1	67	Severe	1	67	PD	Alive at 36 months
		Skin	2		2			2			
		Mouth	1		1			1			
		Joints and fascia	3		3			3			
2	Moderate	PS	1	Moderate	1	0	Moderate	1	0	SD	Alive at 35 months
		Skin	2		2			2			
		Mouth	2		2			2			
3	Severe	PS	1	Moderate	1	40	Moderate	1	72	PR	Alive at 34 months
		Skin	1		1			1			
		Mouth	1		1			1			
		Liver	3		2			2			
		Thrombocytopenia	2		1			1			
		AIHA	1		0			0			
4	Severe	PS	1	Severe	1	0	Severe	1	0	SD	Died of infection at 20 months
		Skin	3		3			3			
		Eye	1		1			1			
		Joints and fascia	3		3			3			
5	Severe	PS	2	Severe	2	-	Severe	2	-	SD	Died of infection at 19 months
		Skin	3		3			3			
		Eye	1		1			1			
		Intestine	1		1			1			
		Joints and fascia	1		1			1			
		Serositis	2		2			2			
		Thrombocytopenia	2		2			1			
6	Moderate	PS	2	Moderate	1	0	Moderate	1	100	PR	Alive at 30 months
		Skin	2		1			1			
		Mouth	2		1			1			
		Eye	2		1			1			
		Muscle	1		0			0			
7	Moderate	PS	1	Moderate	1	0	Moderate	1	25	PR	Alive at 23 months
		Skin	2		2			0			
		Mouth	1		1			1			
		Eye	2		2			2			
		Joints and fascia	1		1			0			

at 1 year, although dry eye and oral mucositis did not improve.

Overall, none of the patients achieved a CR, whereas a PR was noted in 3 patients. SD was noted in 3 patients and PD in 1. One year after rituximab therapy began, PSL was discontinued or reduced in 4 of 6 patients; the median reduction rate was 67% (range 0–100%). None of the 7 patients required additional immunosuppressive therapy within 1 year after the initiation of the study. At a median follow-up of 30 months, 5 patients were alive with active

and continuing chronic GVHD, and 2 had died of infection after the study period.

On the basis of global staging, only 1 patient with “severe” disease improved to “moderate” disease at 1 year, whereas 3 others with “severe” disease experienced no change. Patients with severe (score 3) skin sclerosis and joint contracture related to sclerodermatous skin GVHD and fasciitis did not respond to rituximab therapy. One patient with severe (score 3) hepatic GVHD responded partially to rituximab therapy. Clinical responses were